HANDOK Inc.
Financials
Valuation Metrics
HANDOK Inc.'s Market Cap is ₩1130B. At end of 2025 it was ₩1542B. Ranked #1138 of 2,405 in KR market (top 47%), #544 of 778 on KOSPI (top 70%), #133 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 58%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 113.00B KRW | KR#1,138/2,405 Sec#133/231 |
| Revenue | 560.89B KRW | KR#582/2,405 Sec#29/231 |
| Net Income | -9.45B KRW | KR—/2,405 Sec—/231 |
| Total Assets | 779.69B KRW | KR#564/2,405 Sec#31/231 |
| Net Assets | 255.08B KRW | KR#815/2,405 Sec#53/231 |
| Employees | 988 | KR#258/2,405 Sec#19/231 |
| Value | ||
| P/B | 0.44x | KR#750/2,405 Sec#28/231 |
| P/S | 0.20x | KR#413/2,405 Sec#9/231 |
| EV/EBITDA | 56.33x | KR#1,383/2,405 Sec#92/231 |
| FCF Yield | -8.74% | KR—/2,405 Sec—/231 |
| Profitability | ||
| ROE | -3.71% | KR#1,738/2,405 Sec#123/231 |
| ROA | -1.21% | KR#1,694/2,405 Sec#120/231 |
| Op. Margin | 1.47% | KR#1,449/2,405 Sec#102/231 |
| Revenue Growth | 12.01% | KR#800/2,405 Sec#80/231 |
| Financial Health | ||
| Debt Ratio | 205.66% | KR#2,108/2,405 Sec#220/231 |
| Total Debt | 375.23B KRW | KR#357/2,405 Sec#16/231 |
| FCF | -9.88B KRW | KR#1,695/2,405 Sec#148/231 |
| Cash | 23.30B KRW | KR#1,157/2,405 Sec#79/231 |
| Current Ratio | 0.86x | KR#1,865/2,405 Sec#183/231 |
| Net Debt/EBITDA | 42.64x | KR#1,468/2,405 Sec#102/231 |
| Dividend | ||
| Div. Yield | 2.45% | KR#815/2,405 Sec#42/231 |
| Div. Growth | 0.00% | KR—/2,405 Sec—/231 |
| Performance | ||
| 1Y Return | -27.98% | KR#1,369/2,405 Sec#101/231 |
| 1M Return | -4.09% | KR#620/2,405 Sec#64/231 |
| From 52W High | -32.43% | KR#482/2,405 Sec#33/231 |
| 1Y MDD | -44.49% | KR#729/2,405 Sec#52/231 |
| Trading | ||
| Volume | 3,007 shares | KR#2,213/2,405 Sec#226/231 |
| Trading Value | 24.6M KRW | KR#2,023/2,405 Sec#211/231 |
| Foreign Own. | 2.18% | KR#1,562/2,405 Sec#148/231 |
| Per Share | ||
| EPS | -687 KRW | KR—/2,405 Sec—/231 |
| BPS | 18,533 KRW | KR#562/2,405 Sec#38/231 |
Company Info
Handok, a pharmaceutical company established in 1954 and listed on the securities market in 1976, transferred its healthcare product business division to Handok Healthcare Co., Ltd. It manufactures and sells professional and general medicines, including diabetes treatments like Amaryl, Tenelia, and Lantus, and hypertension treatments such as Aprovasc, Aprovel, and Coaprovel. The company also engages in medical device and diagnostic reagent sales, pharmaceutical contract manufacturing and quality control services, and real estate leasing. Handok is headquartered in Gangnam-gu, Seoul Metropolitan City.